Date: 13-Nov-2019

Biogen and Samsung expand biosimilar deal to cover Lucentis, Eylea and China

After a successful partnership with its biosimilar joint venture Samsung Bioepis, Biogen has decided to expand into more drugs and China, too. Biogen is getting exclusive rights to Samsung Bioepis’ biosimilar versions of two blockbuster eye drugs, namely Roche and Novartis’ Lucentis and Regeneron and Bayer’s Eylea, covering the U.S., Europe, Japan and other key markets. The Big Biotech is also expanding its hold on three marketed anti-TNF copycats—Humira, Enbrel and Remicade biosimilars—to China.